California-based Veracyte hopes to raise as much as $75 million in an initial public offering. The molecular diagnostics firm is the maker of the Afirma thyroid test, which is used to help cut the number of required surgeries by determining whether nodules on a patient's thyroid are benign or cancerous.

Related Summaries